Based on the provided sources, there is no specific information regarding lurbinectedin causing fetal abnormalities. The sources mainly provide information about the drug, its patent, FDA label, and clinical trials. However, it is important to note that the absence of information does not necessarily mean that lurbinectedin is safe for use during pregnancy.
Lurbinectedin is a drug used for the treatment of certain types of cancer, specifically small cell lung cancer (SCLC) and metastatic triple-negative breast cancer (mTNBC). It works by inhibiting the growth of cancer cells [1].
The FDA label for lurbinectedin does not mention any specific data or warnings about fetal abnormalities or use during pregnancy [2]. However, it is important to note that the FDA label may not always include all possible risks or side effects. Therefore, it is recommended to consult with a healthcare professional or refer to the prescribing information for the most up-to-date and comprehensive information.
The clinical trial search on the National Cancer Institute's website does not provide any specific information about lurbinectedin causing fetal abnormalities [3]. It primarily focuses on ongoing clinical trials involving lurbinectedin for various types of cancer.
In conclusion, based on the provided sources, there is no known information regarding lurbinectedin causing fetal abnormalities. However, it is crucial to consult with a healthcare professional for personalized advice and to consider the potential risks and benefits of using lurbinectedin during pregnancy.
Sources:
[1] Drug Patent Watch. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] U.S. Food and Drug Administration. (2020). Lurbinectedin (ZEPZELCA) Injection, for Intravenous Use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] National Cancer Institute. (n.d.). Clinical Trials Search Results - Lurbinectedin. Retrieved from https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-10037